The Latest Breaking News on Pharma

Top pharmaceutical companies purchased electoral bonds amidst regulatory scrutiny, including Hetero, MSN, Divi's, Intas, Lupin, Mankind, Micro Labs, and Natco.

The pharmaceutical industry is expected to expand rapidly due to growing global healthcare needs and advancements in technology. Therefore, fundamentally strong pharma stocks Merck (MRK), AbbVie (ABBV), and GSK plc (GSK) might be ideal additions to your portfolio. Read on.

The pharmaceutical industry is experiencing considerable growth, driven by rising healthcare needs, continuous advances in drug discovery & discovery, and M&A activity. So, investors could keep a close eye on top pharma stocks Amneal Pharmaceuticals (AMRX), Collegium Pharmaceutical (COLL), and Sanofi (SNY) for potential gains. Keep reading….

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading.

The biotech industry’s growth prospects look promising due to innovative drugs and therapies, government initiatives, and technological advancements. Therefore, investors could consider buying fundamentally strong biotech stocks BioMarin Pharmaceutical (BMRN), Illumina (ILMN), and Harmony Biosciences (HRMY). These stocks are B-rated (Buy) in our proprietary rating system. Read on.

The biotech industry is poised for robust growth due to increasing demand for personalized treatments, rising prevalence of chronic diseases, heightened investments in R&D, and advancements in technology. Therefore, investors could consider buying fundamentally strong biotech stocks Innoviva (INVA), ANI Pharmaceuticals (ANIP), and United Therapeutics (UTHR). Read more.

Group advocating to preserve FDA judgment in supreme court case also gave $125,000 to Republicans opposing mifepristone

Biden calls for expanding Medicare drug price negotiations to include up to 500 drugs over next decade.

CEO Bill Anderson, hired last year to help steer the troubled group in a new direction, ruled out any imminent break-up of the company -- despite mounting pressure from activist investors.

The Bench also issued a contempt notice against the company and its Managing Director Acharya Balkrishna for failing to adhere to directions passed in November last year. The “entire country has been taken for a ride”, the Bench said, while reprimanding the Union Government for its failure to take “urgent…

CVS will start filling prescriptions for mifepristone in Massachusetts and Rhode Island. Walgreens will start in New York, Pennsylvania, Massachusetts, California and Illinois.